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SIGNIFICANCE OF THE STUDY 
What is already known about this subject? 
Interval cancers have been observed to occur in biennial gFOBT-based pilot colorectal 
cancer screening programmes in substantial numbers. 
When compared with screen-detected cancers, interval cancers are more likely to arise in 
women and the right colon. 
When compared with screen-detected cancers, more interval cancers are diagnosed at a 
more advanced stage, but not as advanced as cancers arising in non-participants. 
What are the new findings? 
In a fully rolled-out gFOBT screening programme, interval cancers account for around 50% 
of the cancers diagnosed in the screened population. 
Although right-sided cancers are commoner in women, and are more likely to be interval 
cancers, the gender bias favouring screen-detection in men is independent of tumour site. 
Although screen-detected colonic cancers are less advanced at diagnosis than interval 
cancers, this is not the case in the rectum. 
How might it impact on clinical practice in the foreseeable future? 
To achieve informed choice, the risk of interval cancer must be made explicit to the 
population offered screening for colorectal cancer. 
Gender imbalance in screening needs to be addressed by considering the use of gender 
partitioned faecal haemoglobin cut-off concentrations. 
Strategies are required to reduce the interval cancer rates and to improve the early detection 
of rectal cancer. 
 
ABSTRACT 
Objective To study the prevalence and the characteristics of interval cancers arising in the 
Scottish Bowel Screening Programme, and to compare them with screen-detected cancers 
and cancers in non-participants arising in the same time period. 
Design Observational study done in the Scottish Bowel Screening Programme, consisting of 
biennial guaiac faecal occult blood testing (gFOBT) offered as the initial test to all between 
the ages of 50-74 years. All individuals (772,790) invited to participate in bowel screening in 
Scotland between 01/01/2007 and 31/05/2009 were studied by linking their screening 
records with confirmed colorectal cancer records in the Scottish Cancer Registry (SCR). 
Numbers and characteristics of screen-detected (SC), interval (IC) and non-participant 
(NPC) cancers were determined.  
Results In the study period, there were 555 SC, 502 IC and 922 NPC.  Overall, SC were 
diagnosed at an earlier stage than IC and NPC, screening preferentially detected cancers in 
males (as evidenced by the significant gender difference in the proportion of SC and IC), and 
this was independent of a different cancer site distribution in males and females.  Although 
SC in the colon were less advanced than IC, this was not the case in the rectum. 
Conclusion Colorectal IC account for around half of all cancers diagnosed in the screened 
population, indicating a test sensitivity of around 50% for gFOBT.  It is clear that the 
sensitivity of gFOBT is less for women than for men: gFOBT screening may not be effective 
for rectal cancer. 
 
INTRODUCTION 
In the context of iterative cancer screening, the term “interval cancer” denotes a cancer that 
has been diagnosed after a negative screening test result in the interval before the 
participant has had an opportunity to repeat the test.1  Thus, in colorectal cancer (CRC) 
screening programmes that use biennial guaiac faecal occult blood testing (gFOBT) as the 
initial investigation, such as are currently in place across the United Kingdom, an interval 
cancer (IC) represents a cancer that has been diagnosed within two years of a negative test 
result.   
While CRC may arise de novo in the interval between screening invitations, this is almost 
certainly a rare event, and, for the most part interval cancers (IC) are likely to be cancers 
that have been missed by the screening test, either at a non-invasive (adenoma) or an 
earlier invasive stage.  The percentage of cancers arising in the screened population that are 
IC is therefore a key performance indicator of a population screening programme, since it 
provides a pragmatic index of test sensitivity, i.e., the ability of the test to detect CRC. 
Despite this, relatively little is known about IC in CRC screening programmes.  World-wide, 
the most commonly employed non-invasive CRC screening test involves the detection of 
haemoglobin in faeces, and this is predicated on the results of population-based trials of 
gFOBT, all of which demonstrated a reduction in disease-specific mortality with biennial 
screening.2  However, these studies have little data on interval cancers, and there have 
been only two reports describing the pattern of IC occurrence in pilot studies of gFOBT 
screening, one from Scotland3 and one from Catalonia,4 and none from fully rolled out 
national programmes. 
In Scotland, after a demonstration pilot5 based on the Nottingham randomised trial6 and 
running from 01/03/2000 to 31/05/2007 for individuals aged 50-69 years, CRC screening 
was rolled out across the country starting on 01/06/2007 and was offered to all those 
between the ages of 50 and 74 years.  Here, the characteristics of IC arising in all individuals 
invited to participate in the Scottish Bowel Screening Programme between 01/06/2007 and 
31/05/2009 and followed up until 30/11/2011 are reported.  This interval was chosen to allow 
time for reliable identification of the interval cancers from the Scottish Cancer Registry and to 
ensure that complete data for CRC was available on the Registry.  We also compare the IC 
with the screen detected cancers (SC) and the cancers diagnosed in those who chose not to 
participate in screening during the same time period, termed non-participant cancers (NPC).   
METHODS 
When the Scottish Bowel Screening Programme (SBoSP) was rolled out to the rest of the 
country, the screening process differed from that employed in the pilot in two important 
respects.  Firstly, the age range was extended form 50-69 years to 50-74 years.  Secondly, 
instead of using a second gFOBT for a weak positive result (i.e. for those who had one to 
four of the six windows positive in the gFOBT), a qualitative faecal immunochemical test 
(FIT) (hema-screen SPECIFIC, Immunostics Inc, Ocean, NJ, USA) was employed.7   This 
was based on work that had demonstrated improved performance of this novel two-tier reflex 
gFOBT/FIT screening algorithm in terms of fewer false positives.8 
For the purposes of this report, the following definitions were employed: a screen-detected 
cancer (SC) was defined as a CRC diagnosed as a result of investigations (usually 
colonoscopy) carried out in response to a positive test result, an interval cancer (IC) was 
defined as a CRC diagnosed within two years of a negative test result and a non-participant 
cancer (NPC) was defined as a cancer arising in an individual who had been invited to 
participate in the SBoSP but had not done so.  A missed cancer was defined as a CRC 
diagnosed within two years of a negative colonoscopy carried out in response to a positive 
test result and a miscellaneous cancer as a CRC diagnosed in an individual who either 
defaulted before a final test result was achieved, refused investigation after a positive test 
result, was found to be unfit for colonoscopy, was already undergoing investigations for 
symptoms, was admitted as an emergency, or died between screening investigations. 
A right-sided (R) colonic cancer was defined as a cancer recorded as being between the 
caecum and the splenic flexure, a left-sided (L) colonic cancer as a cancer between (and 
including) the splenic flexure and the rectosigmoid junction and a rectal (RE) cancer as a 
cancer in the rectum or recto-sigmoid junction.  There were also a small number of not 
otherwise specified colonic cancers (NoSC), which are included in the analyses for 
completeness. 
In order to categorise the CRC in the manner described above, all screening records were 
linked with confirmed CRC records in the Scottish Cancer Registry (SCR).  This permitted 
the calculation of the time between the final test result being generated and the date that the 
CRC was diagnosed.  
The stage at diagnosis of the CRCs was described using the Dukes’ staging system and, 
although polyp cancers (cancers removed by polypectomy at colonoscopy) were identifiable 
in the SC group, such data were unavailable from the registry data.  Thus, all polyp cancers 
were included in the “A” Dukes’ category for the current analysis. 
Socio-economic deprivation was estimated using the Scottish Index of Multiple Deprivation 
(SIMD), which is based on small area data zones each containing around 250 households 
which can be identified by postcode.  Seven different aspects of deprivation are identified in 
the SIMD: employment, income, health, education, access to services, crime and housing. 
The index provides a relative ranking for each data zone and this is commonly divided into 
quintiles, with quintile 1 representing the most deprived, and 5 the least deprived.  
The SCR utilises multiple sources and routine indicators of data quality indicate very nearly 
complete case ascertainment.  A study of the year 1992 estimated completeness of 
ascertainment of 96.5% for all cancers and 98.5% for CRC.9 
In all cases, the Chi-squared test was used to test the statistical significance of the 
distribution of the results. 
RESULTS 
Between 01/06/2007 and 31/05/2009, 772,790 screening invitations were issued and 
417,354 final test results were obtained (an overall uptake of 54%).  In this population, there 
were 555 SC, 502 IC and 922 NPC diagnosed.  Table 1 shows the complete breakdown of 
all the categories and the overall gender and stage distributions.   
Tables 2-6 show the distribution of gender, stage, tumour site, age and deprivation 
categories in SC, IC and NPC.  Table 2 shows a highly statistically significant difference in 
the gender distribution of SC compared to IC, with a greater preponderance of males in the 
SC than in the IC category.  There were also more males than females amongst the NPC, 
and this was less pronounced than in the SC and more than in the IC groups.  In Table 3, it 
can be seen that the stage distribution was more favourable in the SC group than in both the 
IC and NPC groups, and that the distribution in the IC group was more favourable than in the 
NPC group. The site distribution, shown in Table 4, indicates that R colon cancers were less 
common in the SC group than in either the IC or the NPC groups.  The age distribution 
(Table 5) indicates a younger population in the NPC group than the SC group, but little 
difference between SC and IC or IC and NPC. In Table 6, it is demonstrated that there was a 
trend towards the more deprived end of the spectrum in the NPC group when compared to 
both SC and IC, but no difference between SC and IC groups. 
Overall, when stage was examined by site, it was clear that RE and L colon cancers tended 
to present at an earlier stage than R colon cancers (Table 7) and that males had a lower 
proportion of R colon cancers that females (Table 8).  There did not, however, appear to be 
any significant difference in stage at presentation between males and females (Table 9). 
Since both stage and screen detection are therefore related to site, the stage at presentation 
was broken down by site and screening status (Table 10).  This demonstrated that SC had a 
more favourable stage distribution than IC and NPC in both the R and L colons, but that 
there was no difference between IC and NPC.  In the RE, however, there was no difference 
in the stage distribution between SC and IC, but both had a significantly more favourable 
distribution than NPC. 
Additionally, since screen-detection was found to be related to both gender and site, SC and 
IC were broken down by site for males and females separately.  This is shown in Table 11, 
which demonstrates that SC were more common in males for both R and L cancers, but not 
significantly so for RE. 
DISCUSSION 
This detailed study of cancers diagnosed in the population invited to participate in the 
SBoSP confirms that screen-detected cancers are diagnosed at an earlier stage than 
interval cancers and non-participant cancers, that screening preferentially detects cancers in 
males (as evidenced by the significant gender difference in the proportion of screen detected 
and interval cancers), that cancers in the right colon are less common in the screen-detected 
group, that right-sided colon cancers have a less favourable stage distribution than left-sided 
and that right-sided cancers are less commonly seen in males than females.  In addition to 
confirming, in more detail, previous reports both by our group3 and others3,10, the results 
described here pose two important new questions.  Firstly, since right-sidedness is 
associated with both poorer stage and a resistance to screen-detection, is early diagnosis by 
screening a function of the site of the tumour?  Secondly, since right-sidedness is associated 
with female gender as well as a resistance to screen-detection, is the well-documented 
better sensitivity of gFOBT screening in males compared with females also related to tumour 
site? 
We have been able to answer these questions from this analysis.  It is clear that both right-
sided and left-sided screen-detected colonic cancers do have a more favourable stage 
distribution than either interval cancers or non-participant cancers, indicating that the 
screening process does indeed identify earlier stage disease in the colon.  In the rectum, 
however, this does not seem to be the case.  The stage distribution was very similar in the 
screen-detected and the interval cancers, and both were more favourable than non-
participant cancers.  
It is interesting to speculate why this should be. Rectal cancer more often presents with 
rectal bleeding than colon cancer, and in the Nottingham trial of gFOBT screening, it was 
observed that, during the study, the stage at presentation of rectal cancer improved in the 
control group as well as in the group offered screening, but that this was not seen in colon 
cancer.11  It can be hypothesised that this was caused by a halo effect of the screening 
programme which raised awareness of the significance of the presence of frank blood seen 
in faeces, both in those not offered screening, and amongst general practitioners.  A similar 
argument may be applied to our findings; it is possible that those who had taken up the offer 
of screening had an already heightened awareness of the implications of rectal bleeding, so 
that when this occurred after a negative test result, they engaged with primary care promptly, 
whereas those who had not taken up the offer of screening were less likely to appreciate the 
importance of this symptom, either because they were less health conscious or because 
they had not been exposed to the messages delivered by engaging with the SBoSP. 
We have also been able to show that screen-detection occurs more often in males than in 
females in both the right and the left colon.  This may also be the case in the rectum, 
although this did not reach statistical significance.  Thus the difference in sensitivity of 
gFOBT for CRC between males and females is not explained by the gender difference in 
tumour site.  Why this difference in sensitivity should exist is not clear but, in an evaluation of 
quantitative faecal immunochemical testing (FIT) in a population in Scotland, we have shown 
that men tend to have significantly higher faecal haemoglobin concentrations than 
women.12This finding, although currently of obscure aetiology, may explain the differential 
sensitivity phenomenon.  
Our findings with respect to age and deprivation are also worth comment.  Firstly, the age of 
people diagnosed with screen-detected disease was slightly greater than those with CRC 
who had not participated in screening.  This is in keeping with previous findings that uptake 
of screening and faecal haemoglobin concentrations tend to increase with age,12 and this 
may have the effect of exaggerating the association between age and CRC risk.  Secondly, 
both the screen-detected and interval cancer groups exhibited a deprivation gradient, with 
more cancers being diagnosed in the less deprived categories, and this was not seen 
amongst the non-participants.  This undoubtedly reflects the well-described deprivation 
gradient associated with screening uptake and the decrease of positive predictive value of 
gFOBT with increasing deprivation.13 
CONCLUSIONS 
In summary, this study is the first to address interval cancers in a rolled-out national 
population-based screening programme for colorectal cancer using gFOBT as the initial 
screening modality. It demonstrates that interval cancers make up a substantial proportion of 
cancers diagnosed in the screened population when a biennial gFOBT-based algorithm 
yielding a positivity of around 2% is used, and serves to reinforce current advice to 
participants not to regard a negative test result as a “certificate of health” and not to ignore 
symptoms.   It is likely that the proportion of interval cancers will increase with time, as 
demonstrated in our previous study of three biennial pilot screening rounds,5 but it is not yet 
clear at what level and when this proportion will plateau.  In any event, moving into the 
future, an interval cancer rate of this magnitude is unlikely to be acceptable to the population 
being offered screening and efforts to overcome this problem constitute an essential 
component of screening research and development. 
It is also interesting that rectal cancer is diagnosed at roughly the same stage in the group 
accepting screening regardless of whether or not the gFOBT result is positive or negative, 
suggesting that an alternative strategy may be required to detect rectal cancer more 
effectively through screening. 
Finally, women are at a disadvantage in colorectal cancer screening employing gFOBT, both 
because they are at higher risk of right-sided cancers, which are less likely to generate a 
positive test result, and because they are inherently less likely to have a positive test result 
with CRC at any site. 
The solution to these issues may be multifactorial, and a screening programme that offers 
both faecal testing for the presence of blood and endoscopy of the rectum and distal colon 
may pay dividends.14 equally important, however, is the advent of the use of automated 
quantitative faecal immunochemical test (FIT) analysis which offers a much more flexible 
approach to CRC screening.  Using this technology, it is possible to set the cut-off faecal 
haemoglobin (f-Hb) concentration to suit colonoscopy capacity and to take account of 
gender and age differences in f-Hb concentrations12.  In addition, it is plausible that 
decreasing the cut-off used so as to increase the sensitivity while extending the screening 
interval to offset the increase in colonoscopy demand or determining the screening interval 
on the basis of the index f-Hb could improve the performance of a screening programme.  
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Table 1   Overall distribution of cancers 
 Cancer category % n 
Screen detected cancer 25.7 555 
Interval cancers  23.2 502 
Missed cancers 0.5 12 
Miscellaneous cancers 7.9 170 
Non-participant cancers 42.7 922 
Total 
 
2161 
 
 Gender % n 
Males 59.2 1279 
Females 40.8 882 
 
 Stage % (n) 
A 20.5 442 
B 24.9 539 
C 27.7 599 
D 16.5 356 
Unknown (UK) 10.4 225 
 
 
 
 
 
 
 
Table 2   Distribution of screen-detected (SC), interval (IC) and non-participant (NPC) cancers by gender 
 Gender SC IC NPC 
  %       (n) %       (n) %       (n) 
Male 64.7 (359) 52.8 (265) 59.7 (550) 
Female 35.3 (196) 47.2 (237) 40.3 (372) 
Total   555   502   922 
SC vs IC:  χ2 = 15.42 p<0.0001 
IC vs NPC: χ2 = 6.26 p=0.0123 
SC vs NPC: χ2 = 3.71 p=0.0542 
 
 
Table 3   Distribution of screen-detected (SC), interval (IC) and non-participant (NPC) cancers by stage 
 Stage SC IC NPC 
  %       (n) %        (n) %      (n) 
A 33.9 (188) 18.7 (94) 11.3 (104) 
B 25.6 (142) 25.5 (128) 25.3 (233) 
C 25.2 (140) 28.5 (143) 29.3 (270) 
D 6.3 (35) 18.9 (95) 21.5 (199) 
UK 9 (50) 8.4 (42) 12.6 (116) 
Total   555   502   922 
SC vs IC:  χ2 = 57.97 p<0.0001 
IC vs NPC: χ2 = 19.35 p=0.0007 
SC vs NPC: χ2 = 146.50 p<0.0001 
 
 
 Table 4   Distribution of screen-detected (SC), interval (IC) and non-participant (NPC) cancers by site 
 Site SC IC NPC 
  %      (n) %       (n) %       (n) 
R 27.9 (155) 39.2 (197) 36.0 (332) 
L 37.7 (209) 23.7 (119) 25.0 (230) 
NSC 3.2 (18) 4.8 (24) 5.4 (50) 
RE 31.2 (173) 32.3 (162) 33.6 (310) 
Total   555   502   922 
SC vs IC:  χ2 = 28.33 p<0.0001 
IC vs NPC: χ2 = 1.56 p=0.6694 
SC vs NPC: χ2 = 29.91 p<0.0001 
 
Table 5 Distribution of screen-detected (SC), interval (IC) and non-participant (NPC) cancers by age group 
 Age SC IC NPC 
  %       (n)  %       (n) %      (n) 
50 - 54 8.3 (46) 10.2 (51) 12.7 (117) 
55 - 59 12.2 (68) 12.5 (63) 13.1 (121) 
60 - 64 18.6 (103) 21.5 (108) 19.9 (183) 
65 - 69 26.8 (149) 22.7 (114) 18 (166) 
70 - 74 34.1 (189) 33.1 (166) 36.3 (335) 
Total   555   502   922 
SC vs IC:  χ2 = 4.07 p=0.3969 
IC vs NPC: χ2 = 6.93 p=0.1394 
SC vs NPC: χ2 = 19.79 p=0.0006 
Table 6   Distribution of screen-detected (SC) , interval (IC) and non-participant (NPC) cancers by deprivation category (Depcat) (1- most deprived, 5 – least deprived) 
 
 Depcat SC IC NPC 
  %        (n) %        (n) %       (n) 
1 12.4 (69) 11.5 (58) 17 (157) 
2 19.3 (107) 15.3 (77) 23.4 (216) 
3 19.5 (108) 22.3 (112) 20.2 (186) 
4 25.1 (139) 24.2 (121) 20.6 (190) 
5 23.7 (132) 26.7 (134) 18.8 (173) 
Total   555   502   922 
SC vs IC:  χ2 = 4.53 p=0.3387 
IC vs NPC: χ2 = 28.80 p<0.0001 
SC vs NPC: χ2 = 14.89 p=0. 0075 
 
 
Table 7   Overall relationship between tumour site and stage (R – right colon   L – left colon   NoSC – not otherwise specified colon   RE – rectal including recto-sigmoid) 
 Stage R L NoSC RE 
  %    (n) %    (n) %    (n) %    (n) 
A 13.4 (98) 23.4 (145) 18.4 (18) 25.5 (181) 
B 31.7 (233) 26.7 (165) 16.4 (16) 17.6 (125) 
C 31.6 (232) 24.9 (154) 21.4 (21) 27.1 (192) 
D 17.2 (126) 15.8 (98) 31.6 (31) 14.2 (101) 
UK 6.1 (45) 9.2 (57) 12.2 (12) 15.6 (111) 
Total   734   619   98   710 
                                                                     χ2 = 118.61  DoF = 12  p<0.0001  
 
 Table 8 Overall relationship between tumour site and gender (R – right colon   L – left colon   NoSC – not otherwise specified colon   RE – rectal including recto-sigmoid)    
 Site M F 
  %          (n) %        (n) 
R 29.3 (375) 40.7 (359) 
L 28.9 (370) 28.2 (249) 
NoSC 4.4 (56) 4.8 (42) 
RE 37.4 (478) 26.3 (232) 
Total   1279   882 
                                     χ2 = 39.64 p<0.0001   
 
 
Table 9 Overall relationship between tumour stage and gender 
 Stage Male Female 
  %         (n) %       (n) 
A 22 (281) 18.3 (161) 
B 25 (320) 24.8 (219) 
C 25.7 (328) 30.7 (271) 
D 16.8 (215) 16 (141) 
UK 10.5 (135) 10.2 (90) 
Total   1279   882 
                                        χ2 = 8.67 p=0.069     
 
 
 
Table 10   Relationship between site, screening status and stage (RS – right colon screen-detected  RI – right colon interval   RNP -  right colon non-participant   LS – Left 
colon screen-detected   LI – left colon interval   LNP – left colon non-participant   NoSCS – not otherwise specified colon screen detected  NoSCI – not otherwise specified 
colon interval  NoSCNP – not otherwise specified colon non-participant  ReS – Rectal screen-detected  ReI – rectal interval  ReNP – Rectal non-participant)   
 
  RS RI RNP LS LI LNP NoSCS NoSCI NoSCNS ReS ReI ReNP 
  %  (n) %  (n) %  (n) %  (n) %  (n) % (n)  %  (n) %     (n) %     (n) %  (n) %  (n) %  (n) 
A 25.2 (39) 9.7 (19) 8.8 (29) 37.7 (79) 17.7 (21) 12.1 (28) 38.8 (7) 8.3 (2) 12.0 (6) 36.4 (63) 32.1 (52) 13.2 (41) 
B 41.3 (64) 29.4 (58) 29.8 (99) 21.1 (44) 29.4 (35) 29.6 (68) 16.7 (3) 25.0 (6) 14.0 (7) 17.9 (31) 17.8 (29) 19.0 (59) 
C 27.1 (42) 31.5 (62) 32.2 (107) 22 (46) 31.1 (37) 26.1 (60) 27.8 (5) 29.2 (7) 18.0 (9) 27.2 (47) 22.8 (37) 30.4 (94) 
D 4.5 (7) 22.8 (45) 20.8 (69) 9.1 (19) 16.8 (20) 22.6 (52)  –   29.2 (7) 42.0 (21) 5.2 (9) 14.3 (23) 18.4 (57) 
UK 1.9 (3) 6.6 (13) 8.4 (28) 10.1 (21) 5.0 (6) 9.6 (22) 16.7 (3) 8.3 (2) 14.0 (7) 13.3 (23) 13.0 (21) 19.0 (59) 
Total   155   197   332   209   119   230   18   24   50   173   162   310 
RS vs RI: χ2 = 40.62 p<0.0001                           LS vs LI: χ2 = 20.88 p=0.0011                   NoSCS vs NoSCI: χ2 = 10.67 p=0.0305          ReS vs ReI: χ2 = 8.173 p=0.0854 
RI vs RNP: χ2 = 0.92 p=0.9215                          LI vs LNP: χ2 = 5.66 p=0.2260                  NoSCI vs NoSCNP: χ2 = 3.39 p=0.4951         ReI vs ReNP: χ2 = 24.87 p=0.0001 
RS vs RNP:  χ2 = 50.41 p<0.0001                      LS vs LNP: χ2 = 13.31 p<0.0099               NoSCS vs NoSCNP: χ2 = 13.31 p=0.0099     ReS vs ReNP:  χ2 = 44.46 p<0.0001                             
 
 
 
 
 
 
 
 
 
Table 11   Relationship between gender and site broken down by screening status (R – right colon   L – left colon   NoSC – not otherwise specified colon   RE – rectal 
including recto-sigmoid  MS – male screen-detected  MI – male interval  FS – female screen-detected  FI – female interval) 
 
  R L NoSC RE 
  %         (n) %        (n) %     (n)   %            (n) 
MS 49.4 (88) 70.7 (140) 35.7 (10) 55 (121) 
MI 50.6 (90) 29.3 (58) 64.3 (18) 45 (99) 
Total   178   198   28   220 
          
FS 38.5 (67) 53.1 (69) 57.1 (8) 45.2 (52) 
FI 61.5 (107) 46.9 (61) 42.9 (6) 54.8 (63) 
Total   174   130   14   115 
                   χ2 = 4.27 p=0.0388      χ2 = 10.55 p=0.0012     χ2 = 1.75 p=0.1859     χ2 = 2.89 p=0.0889      
 
